Skip to main content

Afluria Quadrivalent Side Effects

Generic name: influenza virus vaccine, inactivated

Medically reviewed by Drugs.com. Last updated on Mar 2, 2024.

Note: This document contains side effect information about influenza virus vaccine, inactivated. Some dosage forms listed on this page may not apply to the brand name Afluria Quadrivalent.

Applies to influenza virus vaccine, inactivated: intramuscular emulsion. Other dosage forms:

Serious side effects

Along with its needed effects, influenza virus vaccine, inactivated (the active ingredient contained in Afluria Quadrivalent) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking influenza virus vaccine, inactivated:

Less common

Incidence not known

Other side effects

Some side effects of influenza virus vaccine, inactivated may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to influenza virus vaccine, inactivated: intradermal suspension, intramuscular solution, intramuscular suspension, nasal spray.

General

The most common adverse events occurring in greater than 30% of patients (inclusive of all age groups) were local injection site reactions, myalgia, headache, drowsiness/sleepiness, malaise, pain, and abnormal crying.[Ref]

Cardiovascular

Rare (0.01% to 0.1%): Flushing, hot flush

Postmarketing reports: Vasculitis which may be associated with transient renal involvement, vasodilatation, pallor, tachycardia, Henoch-Schonlein purpura

Dermatologic

Common (1% to 10%): Sweating

Rare (0.01% to 0.1%): Pruritus, urticaria, night sweats, rash

Postmarketing reports: Stevens-Johnson syndrome, erythema multiforme, erythema, angioedema, cellulitis, local or generalized non-specific rash

Gastrointestinal

Very common (10% or more): Diarrhea (up to 23.2%), vomiting (up to 10.5%)

Common (1% to 10%): Nausea

Frequency not reported: Gastroenteritis

Postmarketing reports: Abdominal pain, dysphagia, swelling of the mouth, throat, and/or tongue

Hematologic

Uncommon (0.1% to 1%): Lymphadenopathy

Postmarketing reports: Thrombocytopenia

Hypersensitivity

Uncommon (0.1% to 1%): Hypersensitivity

Rare (0.01% to 0.1%): Allergic reactions

Postmarketing reports: Anaphylaxis/anaphylactoid reaction, allergic reactions, and other forms of hypersensitivity such as shock, serum sickness, and angioedema

Local

Very common (10% or more): Injection site pain (up to 66.6%), injection site tenderness (up to 54.1%), injection site erythema (up to 37.3%), injection site itching (up to 28%), injection site swelling/lump (up to 25.9%), injection site induration (up to 17.7%), injection site ecchymosis (up to 11.2%)

Common (1% to 10%): Injection site bruising

Uncommon (0.1% to 1%): Injection site warmth

Rare (0.01% to 0.1%): Injection site discomfort

Postmarketing reports: Injection site cellulitis-like reaction, injection site sterile abscess, injection site reaction[Ref]

Musculoskeletal

Very common (10% or more): Myalgia (up to 38.6%), muscle aches (up to 29%), arthralgia (up to 13%)

Uncommon (0.1% to 1%): Muscular weakness

Postmarketing reports: Arthritis

Nervous system

Very common (10% or more): Drowsiness (up to 37.7%), sleepiness (up to 35.5%), headache (up to 27.8%)

Uncommon (0.1% to 1%): Lethargy

Rare (0.01% to 0.1%): Dizziness, paresthesia, somnolence

Postmarketing reports: Guillain-Barre syndrome (GBS), convulsions/seizures, febrile convulsions, myelitis, encephalomyelitis, transverse myelitis, facial palsy (Bell's palsy), optic neuritis/neuropathy, brachial neuritis, syncope (shortly after vaccination), hypoesthesia, hypokinesia, tremor, syncope, facial or cranial nerve paralysis, encephalopathy, limb paralysis

Ocular

Rare (0.01% to 0.1%): Ocular hyperemia

Postmarketing reports: Eye pain, photophobia, conjunctivitis, eye irritation, eye redness, eye swelling, eyelid swelling

Other

Very common (10% or more): Pain (up to 59%), abnormal crying (up to 41.2%), malaise (up to 38.1%), change of eating habits (21%), fatigue (up to 22%), loss of appetite (up to 16%)

Common (1% to 10%): Shivering, fever, influenza-like symptoms

Rare (0.01% to 0.1%): Vertigo, asthenia

Frequency not reported: Varicella

Postmarketing reports: Chest pain, chills, extensive swelling of injected limb, peripheral swelling, abnormal gait, pain in extremity, feeling hot, body aches

Psychiatric

Very common (10% or more): Irritability/fussiness (up to 54%)

Uncommon (0.1% to 1%): Moaning, restlessness

Postmarketing reports: Insomnia

Respiratory

Uncommon (0.1% to 1%): Cough, oropharyngeal pain

Rare (0.01% to 0.1%): Rhinorrhea

Postmarketing reports: Dyspnea, cough, wheezing, throat tightness, rhinitis, tonsillitis, laryngitis, dysphonia, bronchospasm, asthma, croup

Frequently asked questions

References

1. (2023) "Product Information. Fluarix Tetra 2024 (influenza virus vaccine, inactivated)." GlaxoSmithKline Australia Pty Ltd, 16.0

2. (2023) "Product Information. Fluquadri 2024 (influenza virus vaccine, inactivated)." Sanofi-Aventis Australia Pty Ltd

3. (2019) "Product Information. Fluad Quad 2024 with Attached Needle (influenza virus vaccine, inactivated)." Seqirus Pty Ltd

4. (2023) "Product Information. Flucelvax Quad 2024 with Needle (influenza virus vaccine, inactivated)." Seqirus Pty Ltd

5. (2023) "Product Information. Fluzone High-Dose 2024 with Needle (influenza virus vaccine, inactivated)." Sanofi-Aventis Australia Pty Ltd

6. (2023) "Product Information. Influvac Tetra 2024 (influenza virus vaccine, inactivated)." Viatris Pty Ltd

7. (2023) "Product Information. Afluria Quad 2024 with Attached Needle (influenza virus vaccine, inactivated)." Seqirus Pty Ltd

8. (2023) "Product Information. Vaxigrip Tetra 2024 (influenza virus vaccine, inactivated)." Sanofi-Aventis Australia Pty Ltd

9. (2023) "Product Information. Afluria PF Quadrivalent 2023-2024 (influenza virus vaccine, inactivated)." Seqirus, A CSL Company

10. (2023) "Product Information. Fluarix PF Quadrivalent 2023-2024 (influenza virus vaccine, inactivated)." GlaxoSmithKline

11. (2023) "Product Information. Flublok Quadrivalent 2023-2024 (influenza virus vaccine, inactivated)." sanofi pasteur

12. (2023) "Product Information. Flucelvax Quadrivalent 2023-2024 (influenza virus vaccine, inactivated)." Seqirus, A CSL Company

13. (2023) "Product Information. FluLaval PF Quadrivalent 2023-2024 (influenza virus vaccine, inactivated)." ID Biomedical Corp

14. (2023) "Product Information. Fluzone PF Quadrivalent 2023-2024 (influenza virus vaccine, inactivated)." sanofi pasteur

15. (2023) "Product Information. Fluzone High-Dose Quadrivalent PF 2023-2024 (influenza virus vaccine, inactivated)." sanofi pasteur

16. (2023) "Product Information. Influenza (Split Virion, Inactivated) Vaccine (influenza vaccine)." Sanofi Pasteur

17. (2023) "Product Information. Cell-Based Quadrivalent Influenza Vaccine (influenza vaccine)." Seqirus UK Ltd

18. (2023) "Product Information. Supemtek Quadrivalent (influenza vaccine)." Sanofi

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.